2.57
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché JAGX Giù?
Forum
Previsione
Frazionamento azionario
Jaguar Health Inc Borsa (JAGX) Ultime notizie
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Marco Eagle
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts | JAGX Stock News - GuruFocus
Jaguar Health CEO Reveals Near-Term Catalysts at Emerging Growth Conference Tomorrow - Stock Titan
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - The Courier-Journal
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - The Oklahoman
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Cani - GuruFocus
First Study Site Established for Jaguar Health Study of its FDA - GuruFocus
Jaguar Health Establishes First Site for Canalevia-CA1 Field Study - MarketScreener
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Canine Treatment | JAGX Stock News - GuruFocus
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | JAGX Stock News - GuruFocus
First FDA-Approved Dog Diarrhea Treatment Targets 6M Annual Cases with New Clinical Study - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Call Transcript - MSN
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - The Oklahoman
Jaguar Health Reports First Quarter 2025 Financials - The Columbus Dispatch
Jaguar Health Provides Update on Meeting with FDA Discussing Sta - GuruFocus
Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer By Investing.com - Investing.com South Africa
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer - Akron Beacon Journal
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series | JAGX Stock News - GuruFocus
Jaguar Health to Reveal Critical FDA Feedback on Breakthrough Phase 3 Breast Cancer Trial Results - Stock Titan
Jaguar Health (JAGX) Advances Plans for Crofelemer Application | - GuruFocus
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days - The Columbus Dispatch
Jaguar Health (JAGX) Advances Plans for Crofelemer Application | JAGX Stock News - GuruFocus
Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer - Investing.com
Breakthrough: FDA Meeting Could Fast-Track New Breast Cancer Treatment Following Positive Trial Data - Stock Titan
Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates - ACCESS Newswire
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series - Detroit Free Press
Small-cap biotech Jaguar Health’s stock jumps as it launches treatment for a painful side effect of cancer treatment - MSN
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):